Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Praxis Precision Medicines Inc (PRAX)

Praxis Precision Medicines Inc (PRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Stocks Give Up Early Gains as Nvidia Weighs on Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.36%. Stock indexes...

$SPX : 5,509.01 (+0.62%)
SPY : 549.01 (+0.67%)
$DOWI : 39,331.85 (+0.41%)
DIA : 393.29 (+0.47%)
$IUXX : 20,011.89 (+1.01%)
QQQ : 486.98 (+1.05%)
ZNU24 : 109-140 (-0.03%)
UPS : 134.91 (-0.76%)
IP : 43.50 (+0.37%)
MMM : 101.62 (+1.00%)
NVDA : 122.67 (-1.31%)
GFS : 50.84 (+1.15%)
Invitae's Real-World Ciitizen Data Utilized in Praxis Precision Medicines' PRAX-222 IND Filing

/PRNewswire/ -- Invitae (NYSE: NVTA) and Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that real-world clinical insights from Invitae's...

NVTA : 0.0195 (+2.63%)
IONS : 45.14 (-4.18%)
PRAX : 39.27 (-4.66%)
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2022 Financial Results

PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming...

PRAX : 39.27 (-4.66%)
Praxis Precision Medicines to Present at 2022 Wedbush PacGrow Healthcare Conference

BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 39.27 (-4.66%)
2 Stocks Insiders Are Loving Despite a Volatile Market

The current global macro-economic environment has not been kind to stock market investors. Record-high inflation levels and rising interest rates have resulted in muted returns, making investment decisions...

CMP : 9.93 (-1.29%)
PRAX : 39.27 (-4.66%)
Praxis Precision Medicines Reports Negative Results from PRAX-114 Phase 2/3 Monotherapy Aria Study in Patients with Major Depressive Disorder

Aria Study did not achieve statistical significance on the primary endpoint Strategic realignment to focus resources on Movement Disorders and Epilepsy...

PRAX : 39.27 (-4.66%)
Praxis Precision Medicines Adds Global Business Expertise to Board of Directors with Appointment of Jill DeSimone

BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 39.27 (-4.66%)
Praxis Precision Medicines to Present at Upcoming Investor Conferences

BOSTON, May 11, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic...

PRAX : 39.27 (-4.66%)
Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study Mean improvement at Day 42 was...

PRAX : 39.27 (-4.66%)
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2022 Financial Results

PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study PRAX-114 Phase 2/3 monotherapy...

PRAX : 39.27 (-4.66%)

Barchart Exclusives

3 Top-Rated Dividend Kings Trading Near Their 52-Week Lows
These quality companies all have something in common: They are trading a little off their 52-week lows and pay an ever-increasing dividend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar